Alkem Laboratories

Alkem Laboratories FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Alkem Laboratories (ALKEM.NS) as of Oct 21, 2026 is 58.47 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 57.13 % — a change of 2.33% (higher).

FCF Conversion

58.47 %

YoY

2.33%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Alkem Laboratories is 2026 58.47 % . FCF Conversion Rate (FCF/EBITDA) of Alkem Laboratories was 2025 57.13 % . It decreases by 2.33% higher compared to the previous year.

The Alkem Laboratories FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
32.64 INR
Jan 1, 2020
19.70 INR
Jan 1, 2021
67.51 INR
Jan 1, 2022
46.92 INR
Jan 1, 2023
147.29 INR
Jan 1, 2024
94.04 INR
Jan 1, 2025
57.13 INR
Jan 1, 2026
58.47 INR
The Alkem Laboratories FCF Conversion history
YEARFCF ConversionYoY
58.47 %+2.33%
57.13 %-39.25%
94.04 %-36.15%
147.29 %+213.91%
46.92 %-30.49%
67.51 %+242.74%
19.70 %-39.66%
32.64 %-150.53%
-64.60 %+231.74%
-19.47 %-130.81%
63.19 %+32.11%
47.83 %+12.70%
42.44 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Alkem Laboratories Stock analysis

What does Alkem Laboratories do? Alkem Laboratories Ltd is a leading Indian pharmaceutical company that was founded in 1973 and is headquartered in Mumbai. The company's main business model includes the development, manufacturing, and distribution of pharmaceutical formulations and active ingredients. Alkem Laboratories specializes in generics, branded drugs, and biosimilars, offering a comprehensive range of medical solutions. The company is divided into several divisions, including drug research and development, manufacturing, marketing, and sales. It focuses particularly on chronic diseases such as diabetes, cardiovascular diseases, cancer, neurological disorders, and infectious diseases. Alkem Laboratories employs over 20,000 employees worldwide and aims to improve the health and well-being of people globally. It offers a wide range of both prescription and over-the-counter products, including antibiotics, antifungals, cardiology, gastroenterology, urology, neurology, oncology, psychiatry, dermatology, and pediatrics. The company is committed to developing biosimilars that provide more affordable treatment options for serious diseases such as cancer and autoimmune diseases. It has developed an extensive portfolio of biosimilars, including Rituximab, Trastuzumab, and Adalimumab. Alkem Laboratories has also invested in research and development to create innovative solutions for the healthcare industry. It has established research centers in India, the USA, and Europe to discover new active ingredients, optimize processes, and develop innovative products. The company aims to lead in maintaining the highest quality standards and complying with strict regulatory requirements. Alkem Laboratories has certified facilities in India and the USA according to GMP guidelines. It also has a strong presence in the international pharmaceutical industry community and is a member of organizations such as the International Generic and Biosimilar Medicines Association, the Indian Pharmaceutical Alliance, and the US Pharmaceutical Research and Manufacturers of America. Overall, Alkem Laboratories is characterized by its extensive experience in the pharmaceutical industry and its commitment to the health and well-being of people worldwide. The company strives to create innovative solutions for the medical sector and aims to utilize its cutting-edge technology and expertise to meet the needs of patients globally. Alkem Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alkem Laboratories stock

FCF Conversion Rate (FCF/EBITDA) of Alkem Laboratories is 58.47 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Alkem Laboratories changed from 57.13 % to 58.47 %, representing a 2.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Alkem Laboratories since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Alkem Laboratories with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Alkem Laboratories

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Alkem Laboratories